Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats

References

• Arakawa H, Kubo H, Washio I, Staub AY, Nedachi S, Ishiguro N, Nakanishi T, Tamai I. 2019. Rat kidney slices for evaluation of apical membrane transporters in proximal tubular cells. J Pharm Sci. 108(8):2798–2804.
   PubMed Web of Science ®Google Scholar
• Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. 2019. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 10(5):1299–1306.
   PubMed Web of Science ®Google Scholar
• Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, Dishy V, Zahir H. 2018. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 6(5):e00418.
   PubMed Web of Science ®Google Scholar
• Choi YH, Kim SG, Lee MG. 2006. Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal first-pass effects. J Pharm Sci. 95(11):2543–2552.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
   PubMed Web of Science ®Google Scholar
• Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y. 2018. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 365(3):573–582.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. 2009. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 86(4):396–402.
   PubMed Web of Science ®Google Scholar
• Hirschberg R, Kopple JD. 1989. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest. 83(1):326–330.
   PubMed Web of Science ®Google Scholar
• Ikemura K, Nakagawa E, Kurata T, Iwamoto T, Okuda M. 2013. Altered pharmacokinetics of cimetidine caused by down-regulation of renal rat organic cation transporter 2 (rOCT2) after liver ischemia-reperfusion injury. Drug Metab Pharmacokinet. 28(6):504–509.
   PubMed Web of Science ®Google Scholar
• Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y. 2012. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 340(2):393–403.
   PubMed Web of Science ®Google Scholar
• Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, Ishizuka H. 2018. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 7(6):661–669.
   PubMed Web of Science ®Google Scholar
• Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ, Shim CK. 2009. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res. 26(3):549–559.
   PubMed Web of Science ®Google Scholar
• Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. 2019. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 160(5):1175–1185.
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. 2005. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 20(5):379–386.
   PubMedGoogle Scholar
• Kitano Y, Kai K, Yamamura N, Yoshiba S, Kuroha M. 2019. Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg, 5 mg, 10 mg, 15 mg). Folia Pharmacol Jpn. 154(6):352–361.
   PubMedGoogle Scholar
• Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y. 2013. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol. 273(1):100–109.
   PubMed Web of Science ®Google Scholar
• Lin JH, Los LE, Ulm EH, Duggan DE. 1987. Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos. 15(2):212–216.
   PubMed Web of Science ®Google Scholar
• Liu T, Meng Q, Wang C, Liu Q, Guo X, Sun H, Peng J, Ma X, Kaku T, Liu K. 2012. Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. Toxicol Appl Pharmacol. 264(3):423–430.
   PubMed Web of Science ®Google Scholar
• Melzer J. 2013. Pharmacology and physiology for anesthesia. Amsterdam: Elsevier. Chapter 32, Renal physiology; p. 561–573.
   Google Scholar
• Ohta K, Inoue K, Hayashi Y, Yuasa H. 2006. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 34(11):1868–1874.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Hochman JH, Meng Y, Pudvah NT, Barrish A, Ma B, Yamazaki M, Fernandez-Metzler C, Lin JH. 2004. Renal elimination of a novel and potent αvβ3 integrin antagonist in animals. Xenobiotica. 34(11-12):1059–1074.
   PubMed Web of Science ®Google Scholar
• Suzuki CAM, Hierlihy SL. 1993. Renal clearance of domoic acid in the rat. Food Chem Toxicol. 31(10):701–706.
   PubMed Web of Science ®Google Scholar
• Tachibana M, Yamamura N, Atiee GJ, Hsu C, Warren V, He L, Dishy V, Zahir H. 2018. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: a phase 1, randomized, open-label, drug-drug interaction study. Br J Clin Pharmacol. 84(10):2317–2324.
   PubMed Web of Science ®Google Scholar
• Terada T, Masuda S, Asaka J, Tsuda M, Katsura T, Inui K. 2006. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 23(8):1696–1701.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, Inui K. 2009. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 329(1):185–191.
   PubMed Web of Science ®Google Scholar
• Umehara K, Iwatsubo T, Noguchi K, Kamimura H. 2007. Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: insight into the development of drug candidates. Xenobiotica. 37(6):618–634.
   PubMed Web of Science ®Google Scholar
• Urakami Y, Okuda M, Masuda S, Saito H, Inui K. 1998. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 287(2):800–805.
   PubMed Web of Science ®Google Scholar
• Van Aubel RA, Masereeuw R, Russel FG. 2000. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol. 279(2):F216–232.
   PubMed Web of Science ®Google Scholar
• Wabner CL, Chen TS. 1987. Aging changes in renal handling of p-aminohippurate. Am J Physiol. 252(5 Pt 2):R871–R877.
   PubMedGoogle Scholar
• Winston JA, Safirstein R. 1985. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 249(4 Pt 2):F490–F496.
   PubMedGoogle Scholar
• Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, Warren V, Vashi V. 2021. Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel α2δ ligand, in healthy volunteers following oral administration. Xenobiotica. 51(5):549–563.
   PubMed Web of Science ®Google Scholar
• Yamamura N, Uchiyama M, Takahashi M, Honda T, Nishiya Y. 2022a. Pharmacokinetics and metabolism of mirogabalin, a novel α2δ ligand, in rats and monkeys. Xenobiotica. 52(1):54–64.
   PubMed Web of Science ®Google Scholar
• Yamamura N, Mikkaichi T, Itokawa K, Hoshi M, Damme K, Geigner S, Baumhauer C. 2022b. Mirogabalin, a novel α2δ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K. Xenobiotica. 52(9–11):997–1009.
   PubMed Web of Science ®Google Scholar